Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/03/2020 07/06/2020 07/07/2020 07/08/2020 07/09/2020 Date
82.38(c) 83.47(c) 83.1(c) 82.5(c) 81.9(c) Last
2 548 821 3 205 026 3 226 933 3 256 966 3 528 929 Volume
-0.79% +1.32% -0.44% -0.72% -0.73% Change
More quotes
Financials (USD)
Sales 2020 50 072 M - -
Net income 2020 9 059 M - -
Net Debt 2020 17 309 M - -
P/E ratio 2020 21,8x
Yield 2020 3,61%
Sales 2021 53 229 M - -
Net income 2021 10 754 M - -
Net Debt 2021 11 938 M - -
P/E ratio 2021 18,3x
Yield 2021 3,74%
Capitalization 192 B 192 B -
EV / Sales 2020 4,18x
EV / Sales 2021 3,83x
Nbr of Employees 109 000
Free-Float 84,4%
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (20.5%; Sandoz). Net sales... 
Sector
Pharmaceuticals
Calendar
07/21Earnings Release
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
01:41aNOVARTIS : Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of..
PU
07/09New $1 billion fund aims to steer antibiotic companies in tough market
RE
07/09New $1 billion fund aims to steer antibiotic companies in tough market
RE
07/08Genmab A/S - Major Shareholder Announcement
AQ
07/08NOVARTIS : Sandoz collaborates with Civica Rx to help reduce critical generic me..
AQ
07/07Understanding the Value Proposition in Timber Pharmaceuticals May Expose the ..
AQ
07/03NOVARTIS : resolves legacy litigation matters, finalizing settlement of speaker ..
AQ
07/02NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/02NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/02NOVARTIS : resolves legacy litigation matters, finalizing settlement of speaker ..
AQ
07/02NOVARTIS : Sandoz reviewing options after Federal Circuit upholds lower court ru..
AQ
07/02NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/02NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/02NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/02Novartis pays $729 million to settle U.S. kickback charges
RE
More news
News in other languages on NOVARTIS AG
01:45aNovartis fait publier une étude sur l'Enerzair Breezhaler dans le Lancet
01:41aNOVARTIS : Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of..
01:35aNovartis sieht Wirksamkeit von Enerzair Breezhaler mit Daten bestätigt
12:31aZURICH STOCK EXCHANGE : 4-Wochenvorschau Schweiz
07/09Pharmaindustrie schafft Milliardenfonds für neue Antibiotika
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Stock Trading Strategies
NOVARTIS AG - 06/16
The stock approaches again the support level
BUY
More Stock Trading Analysis
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 102,94 $
Last Close Price 87,08 $
Spread / Highest target 48,8%
Spread / Average Target 18,2%
Spread / Lowest Target -11,6%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.88%192 070
JOHNSON & JOHNSON-1.78%377 458
ROCHE HOLDING AG5.27%299 642
MERCK & CO., INC.-15.68%196 678
PFIZER, INC.-14.60%187 476
ABBVIE INC.10.62%174 965